KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Acquisitions (2023 - 2024)

Recursion Pharmaceuticals (RXRX) has disclosed Acquisitions for 2 consecutive years, with -$277.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Acquisitions fell 390387.32% year-over-year to -$277.1 million, compared with a TTM value of -$277.0 million through Dec 2024, down 390287.32%, and an annual FY2024 reading of -$277.1 million, down 14927.33% over the prior year.
  • Acquisitions was -$277.1 million for Q4 2024 at Recursion Pharmaceuticals, down from $71000.0 in the prior quarter.
  • Across five years, Acquisitions topped out at $71000.0 in Q4 2023 and bottomed at -$277.1 million in Q4 2024.